Healthcare
Greenwich LifeSciences, Inc.(GLSI)
Live Price
Offline$23.38
-2.54% today
1Y Change
+159.78%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $320.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -75.4%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Greenwich LifeSciences, Inc. (GLSI) is a Healthcare stock with a market cap of $320.00M and listed on NASDAQ. The stock last traded around $23.38 and up 159.8% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -75.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -75.4%, free cash flow -12.2% with operating margin 0.0% and ROIC -896.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines GLSI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 19, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -75.4%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 19, 2026 | โ | +3.8% | +11.1% | -8.8% |
2026 Mar 31, 2026 | โ | -4.4% | +0.7% | -10.1% |
2025 Nov 14, 2025 | +0.0% | -1.1% | -2.0% | +23.9% |
Benchmark Edge
GLSI vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GLSI
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GLSI Max Drawdown
-37.15%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GLSI and SPY.
Company Overview
Greenwich LifeSciences, Inc.
NASDAQ Capital Market
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
- Leadership
- Snehal S. Patel
- IPO Date
- Sep 25, 2020
- Employees
- 4
- Street Address
- Building 14
- Mailing
- Stafford, TX, 77477
- Region
- Stafford, TX, US
- Reporting Currency
- USD
- Investor Line
- 832 819 3232
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 144.3
Growth
- Revenue
- 0.0%
- EPS
- -75.4%
- Free Cash Flow
- -12.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -1042.8%
- ROIC
- -896.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 2.35
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.